Hm Payson & CO Regeneron Pharmaceuticals, Inc. Transaction History

Hm Payson & CO

$5.81 Billion
Q3 2024

A detailed history of Hm Payson & CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Hm Payson & CO holds 16 shares of REGN stock, worth $10,767. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1 1500.0%

Holding current value

$10,767

Previous $1,000 1500.0%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$1024.09 - $1201.76 $15,361 - $18,026	15 Added 1500.0%	16 $16,000
Q2 2024 Aug 13, 2024	BUY	$883.2 - $1071.19 $883 - $1,071	1 New	1 $1,000
Q1 2023 Apr 18, 2023	BUY	$680.49 - $826.97 $10,207 - $12,404	15 New	15 $12,000
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $548 - $738	1 New	1 $0
Q4 2019 Feb 18, 2020	SELL	$274.13 - $376.51 $8,223 - $11,295	-30 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$273.46 - $318.39 $19,142 - $22,287	-70 Reduced 70.0%	30 $8,000
Q2 2019 Aug 15, 2019	BUY	$299.6 - $414.82 $29,960 - $41,482	100 New	100 $31,000

Others Institutions Holding REGN

# of Institutions

1,500

Shares Held

83M

Call Options Held

1.22M

Put Options Held

1.5M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $72.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.

Account